

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

EVERGREEN THERAGNOSTICS, INC.

Petitioner

– vs. –

ADVANCED ACCELERATOR APPLICATIONS SA

Patent Owner

CASE NO. PGR2021-00003

**DECLARATION OF STEPHAN MAUS
UNDER 37 C.F.R. § 1.68
IN SUPPORT OF PETITION FOR
POST GRANT REVIEW OF U.S. PATENT NO. 10,596,276
(ALL CLAIMS)**

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	BACKGROUND AND QUALIFICATIONS	7
III.	PATENT LAW BACKGROUND	9
	A. Level of Ordinary Skill in the Art.....	11
	B. The Scope and Content of the Prior Art.....	12
	C. Differences Between the Prior Art and What Was Claimed.....	12
	D. Objective Evidence of Non-Obviousness	13
IV.	BACKGROUND OF THE TECHNOLOGY AS OF 2018.....	15
V.	THE '276 PATENT (EX. 1001)	26
VI.	THE LEVEL OF ORDINARY SKILL IN THE ART.....	35
VII.	CLAIM CONSTRUCTION	36
VIII.	DETAILED ANALYSIS	41
	A. Overview of the Prior Art.....	44
	B. Independent Claim 1 and Dependent Claims 2-9 and 12-14 of the '276 Patent Would Have Been Obvious Over the Maus Article (Ex. 1009) in View of the '536 Patent (Ex. 1013)	57
	C. Dependent Claims 10, 11, and 17 of the '276 Patent Would Have Been Obvious Over the Maus Article (Ex. 1009) in View of the '536 Patent (Ex. 1013) and De León-Rodríguez (Ex. 1014) and/or Other Prior Art Disclosing That it Was Routine to Maintain pH With an Acetic Acid/Sodium Acetate Buffer During Complexation	89
	D. Dependent Claim 16 of the '276 Patent Would Have Been Obvious Over the Maus Article (Ex. 1009) in View of the '536 Patent (Ex. 1013) and Kwekkeboom (Ex. 1010) or Other Prior Art Disclosing That it Was Routine to Conduct the ¹⁷⁷ LuCl ₃ /DOTA- TATE Reaction in an HCl-Containing Solution.....	99

Declaration of Stephan Maus Under 37 C.F.R. § 1.68 in Support of
Petition for Post Grant Review of U.S. Patent No. 10,596,276

- E. Dependent Claim 18 of the '276 Patent Would Have Been Obvious Over the Maus Article (Ex. 1009) in View of the '536 Patent (Ex. 1013) and General Knowledge that Ascorbic Acid and Sodium Ascorbate are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015).....102
- F. Dependent Claims 15 and 19 of the '276 Patent Would Have Been Obvious Over the Maus Article (Ex. 1009) in View of the '536 Patent (Ex. 1013) and Prior Art Disclosing that it was Routine to Store Radiolabeled Pharmaceuticals in a Stoppered Vial.....104
- G. Claims 20-24 are Anticipated by the Maus Article (Ex. 1009)108
- H. If the Process Limitations Are Considered, Claims 20-24 Would Have Been Obvious Over the Maus Article (Ex. 1009) in View of the '536 Patent (Ex. 1013).....124
- I. Independent Claim 1 and Dependent Claims 2-15 and 17-19 of the '276 Patent Would Have Been Obvious Over Protocol (Ex. 1012) in View of the Maus Article (Ex. 1009), the '536 Patent (Ex. 1013), De León-Rodríguez (Ex. 1014) and/or Other Prior Art Disclosing That it Was Routine to Maintain pH with an Acetic Acid/Sodium Acetate Buffer During Complexation, and General Knowledge that Ascorbic Acid and Sodium Ascorbate Are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015).....133
- J. Dependent Claim 16 of the '276 Patent Would Have Been Obvious Over Protocol (Ex. 1012) in View of the Maus Article (Ex. 1009), the '536 Patent (Ex. 1013), Kwekkeboom (Ex. 1010), De León-Rodríguez (Ex. 1014) and/or Other Prior Art Disclosing that it Was Routine to Maintain pH with an Acetic Acid/Sodium Acetate Buffer During Complexation, and General Knowledge that Ascorbic Acid and Sodium Ascorbate Are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015).....186
- K. Dependent Claims 20-24 of the '276 Patent Are Anticipated by Protocol (Ex. 1012)189
- L. If the Process Limitations Are Considered, Claims 20-24 of the '276 Patent Would Have Been Obvious Over Protocol (Ex. 1012)

Declaration of Stephan Maus Under 37 C.F.R. § 1.68 in Support of
Petition for Post Grant Review of U.S. Patent No. 10,596,276

	in View of the Maus Article (Ex. 1009), the '536 Patent (Ex. 1013), and General Knowledge that Ascorbic Acid and Sodium Ascorbate Are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015).....	201
M.	Claim 24 of the '276 Patent is Not Enabled if the Recited Stability Limitation is Not an Inherent Property of the Pharmaceutical Aqueous Solutions Taught in the Prior Art.....	203
IX.	CONCLUSION	208

...

EXPERT DECLARATION OF STEPHAN MAUS

I, Stephan Maus, hereby declare that:

I. INTRODUCTION

1. I have been retained as an expert witness on behalf of Evergreen Theragnostics, Inc. (“Petitioner”) relating to a petition for post grant review (“PGR”) of U.S. Patent No. 10,596,276 (Ex. 1001, “the ’276 patent”). I am being compensated at a rate of \$500/hour for the time I spend on this matter. My compensation is not affected by the outcome of this proceeding.

2. More specifically, I have been asked to provide my opinions regarding whether the claims of the ’276 patent are unpatentable because they would have been anticipated by, and/or obvious in view of, the prior art at the time of the alleged invention. It is my opinion, for the reasons set forth below, that the claims of the ’276 patent are anticipated by the prior art and/or would have been obvious to a person of ordinary skill in the art (“POSA”) at the time of the alleged invention in the ’276 patent.

3. In forming the opinions expressed in this declaration, I relied upon my education and experience in the relevant field of art, and have considered the viewpoint of a POSA as of July 25, 2018. I have carefully read the ’276 patent, along with portions of its prosecution history. In forming my opinions, I have considered:

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.